TVRD•benzinga•
Oppenheimer Initiates Coverage On Tvardi Therapeutics with Outperform Rating, Announces Price Target of $65
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 21, 2025 by benzinga